1.Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma.
Seung Up KIM ; Jeon Han PARK ; Hyon Suk KIM ; Jae Myun LEE ; Hyun Gyu LEE ; Hyemi KIM ; Sung Hoon CHOI ; Shinhwa BAEK ; Beom Kyung KIM ; Jun Yong PARK ; Do Young KIM ; Sang Hoon AHN ; Jong Doo LEE ; Kwang Hyub HAN
Yonsei Medical Journal 2015;56(5):1296-1306
PURPOSE: Dickkopf-1 (DKK-1) is a Wnt/beta-catenin signaling pathway inhibitor. We investigated whether DKK-1 is related to progression in hepatocellular carcinoma (HCC) cells and HCC patients. MATERIALS AND METHODS: In vitro reverse-transcription polymerase chain reaction (RT-PCR), wound healing assays, invasion assays, and ELISAs of patient serum samples were employed. The diagnostic accuracy of the serum DKK-1 ELISA was assessed using receiver operating characteristic (ROC) curves and area under ROC (AUC) analyses. RESULTS: RT-PCR showed high DKK-1 expression in Hep3B and low in 293 cells. Similarly, the secreted DKK-1 concentration in the culture media was high in Hep3B and low in 293 cells. Wound healing and invasion assays using 293, Huh7, and Hep3B cells showed that DKK-1 overexpression promoted cell migration and invasion, whereas DKK-1 knock-down inhibited them. When serum DKK-1 levels were assessed in 370 participants (217 with HCC and 153 without), it was significantly higher in HCC patients than in control groups (median 1.48 ng/mL vs. 0.90 ng/mL, p<0.001). The optimum DKK-1 cutoff level was 1.01 ng/mL (AUC=0.829; sensitivity 90.7%; specificity 62.0%). Although DKK-1 had a higher AUC than alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) (AUC=0.829 vs. 0.794 and 0.815, respectively), they were statistically similar (all p>0.05). When three biomarkers were combined (DKK-1 plus AFP plus DCP), they showed significantly higher AUC (AUC=0.952) than single marker, DKK-1 plus AFP, or DKK-1 plus DCP (all p<0.001). CONCLUSION: DKK-1 might be a key regulator in HCC progression and a potential therapeutic target in HCC. Serum DKK-1 could complement the diagnostic accuracy of AFP and DCP.
Area Under Curve
;
Biomarkers/blood/metabolism
;
Biomarkers, Tumor/blood
;
Carcinoma, Hepatocellular/blood/*diagnosis
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Intercellular Signaling Peptides and Proteins/*blood/*metabolism
;
Liver Neoplasms/blood/*diagnosis
;
Male
;
Middle Aged
;
Protein Precursors/blood/metabolism
;
Prothrombin/metabolism
;
ROC Curve
;
Reverse Transcriptase Polymerase Chain Reaction/*methods
;
Sensitivity and Specificity
;
alpha-Fetoproteins/analysis/metabolism